atorvastatin has been researched along with Diabetes Mellitus in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (37.65) | 29.6817 |
| 2010's | 42 (49.41) | 24.3611 |
| 2020's | 11 (12.94) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PS; Li, YH; Lin, HW; Lin, JL; Lin, SH; Tsai, LM | 1 |
| Corbella, E; Corbella, X; Díaz-Díaz, JL; Martínez-Porqueras, R; Pintó, X; Rodríguez-Sánchez, MA; Ruíz-García, A; Sánchez-Ruíz-Granado, E; Sarasa, I; Suárez-Tembra, M; Trias, F | 1 |
| Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C | 1 |
| Jin, ES; Kim, J; Kim, KJ; Kim, SE; Kim, Y; Park, M; Park, RW; Park, YM; Rhee, SY; Seo, SI; Seo, WW; Shin, WG; Yoo, JJ; You, SC | 1 |
| Elawady, AS; Elnagar, GM; Elseweidy, MM; Sobh, MS | 1 |
| Ahn, CM; Cho, HJ; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yoon, J | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Ali, AEA; Ali, SI; Elseweidy, MM; Hammad, SK; Shershir, NI | 1 |
| Carvalho, D; Rodrigues, E; Saavedra, A | 1 |
| Beaulieu, S; Cervantes, P; Christensen, BM; D'Apolito, L; Dols, A; Fotso Soh, J; Herrmann, N; Levinson, A; Linnaranta, O; Low, N; Mucsi, I; Müller, D; Mulsant, BH; Platt, RW; Rajji, T; Rej, S; Renaud, S; Saury, S; Schaffer, A; Su, CL; Torres-Platas, G; Trepiccione, F | 1 |
| Cha, KS; Chae, SC; Choi, BG; Choi, CU; Choi, JY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JW; Kim, W; Na, JO; Oh, SK; Park, CG; Park, Y; Rha, SW; Seo, HS; Seong, IW; Yoon, CH | 1 |
| Abbas, F; Abbasi, F; Harris, CS; Harris, V; Kim, SH; Knowles, JW; Lamendola, C; Reaven, GM; Reaven, PD; Snyder, MP; Tripathi, P; Tsai, MS | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Baik, SJ; Cho, JH; Choi, IY; Jeong, YJ; Kim, H; Kim, HS; Kim, TM; Lee, H; Lee, SH; Yang, SJ; Yim, HW; Yoon, KH | 1 |
| Geng, Q; Guo, L; Liu, Y; Liu, Z; Ma, H; Wang, P; Xie, H; Zhan, H; Zhang, G | 1 |
| El-Barbari, AA; El-Tamalawy, MM; Hassan, TM; Ibrahim, OM | 1 |
| Cho, GY; Jung, JH; Kim, HK; Kim, HL; Kim, YJ; Lee, SP; Park, JB; Sohn, DW; Yoon, YE | 1 |
| Chae, IH; Cho, YJ; Cho, YS; Choi, DJ; Kang, J; Kang, SH; Kim, S; Kim, YC; Oh, IY; Park, JJ; Suh, JW; Yoon, CH; Yoon, YE; Youn, TJ | 1 |
| Al Awadhi, M; Al Mahmeed, W; Al Tamimi, O; Al-Hinai, AT; Al-Mahruqi, F; Al-Rasadi, K; Al-Zakwani, I; Arafah, M; Santos, RD; Shehab, A | 1 |
| Chen, XH; Deng, YQ; Tan, Y; Wu, FL; Wu, XM; Yang, DJ; Zhang, XW; Zhou, F | 1 |
| Aimaretti, G; Busti, A; Caputo, M; Castello, L; Chasseur, L; Karamouzis, I; Marzullo, P; Mele, C; Pagano, L; Ponziani, MC; Prodam, F; Samà, MT; Zavattaro, M | 1 |
| Brown, TM; Carson, AP; Colantonio, LD; Dai, Y; Farkouh, ME; Giustino, G; Monda, KL; Muntner, P; Rosenson, RS | 1 |
| Chae, SC; Cho, MC; Choi, BG; Choi, CU; Choi, JY; Hwang, SY; Jang, WY; Jeong, MH; Kim, CJ; Kim, DY; Kim, EJ; Kim, HS; Kim, JW; Kim, W; Kim, YJ; Lee, S; Na, JO; Park, CG; Park, EJ; Rha, SW; Seo, HS | 1 |
| Takaguri, A | 1 |
| Chen, H; Chen, X; Chen, Y; Dong, J; Ge, J; Jiang, XC; Wang, L; Zhang, X | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Al-Hamaq, AO; Barakat, L; Bener, A; Dogan, M | 1 |
| Barter, PJ; DeMicco, DA; Messig, M; Ong, KL; Rye, KA; Waters, DD | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Akkala, RG; Ali, J; Choi, B; Choi, CU; Choi, JW; Choi, SY; Kim, E; Kim, J; Kim, JW; Kim, S; Lee, GN; Lee, JJ; Lee, S; Li, H; Lim, HE; Na, JO; Ngow, HA; Noh, YK; Oh, DJ; Park, CG; Park, JY; Rha, SW; Ryu, SK; SeogSeo, H; Xu, S | 1 |
| Ambegaonkar, B; Davies, G; Ejzykowicz, F; Hsu, TY; Laires, PA | 1 |
| Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L | 1 |
| Zhao, SP; Zhao, W | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Amirsheardost, Z; Hajhashemi, V; Minaiyan, M; Naserzadeh, P; Pourahmad, J; Sadighara, M; Salimi, A; Seydi, E | 1 |
| Antunes, TT; Barreto, PA; Bruder-Nascimento, T; Callera, G; Cat, AN; Ferreira, NS; He, Y; Montezano, AC; Olivon, VC; Tostes, RC; Touyz, RM | 1 |
| Deedwania, P; Singh, V | 1 |
| Benner, JS; Foody, JM; Jeffers, BW; Joyce, AT; Liu, LZ | 1 |
| Cziraky, M; Grochulski, D; Hoy, T; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Clementi, F; Di Luozzo, M; Luciani, G; Mango, R; Martuscelli, E; Mehta, JL; Pizzuto, F; Romeo, F; Trivisonno, A | 1 |
| Kishi, T; Okamatsu, S; Sunagawa, K; Yamada, A | 1 |
| Blann, AD; Goon, PK; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM | 1 |
| Tasci, I | 1 |
| Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Arai, H; Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Birnbaum, H; Ivanova, J; Kuznik, A; Ramakrishnan, K; Signorovitch, J; Simpson, RJ | 1 |
| Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N | 1 |
| Blann, AD; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Chan, WC; Hopkins, R; Jackson, G; Lawes, CM; Marshall, R; Thornley, S; Young, R | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 1 |
| Akhlaghi, F; Dostalek, M; Gohh, RY; Macwan, JS; Paryani, KR; Sam, WJ | 1 |
| Ravnskov, U | 1 |
| Ceska, R; Kasalová, Z; Prázný, M; Skrha, J; Stulc, T; Vrablík, M | 1 |
| Philips, JC; Radermecker, RP; Scheen, AJ | 1 |
| Klose, G | 1 |
| Ganda, OP | 1 |
| McFarlane, SI; Murad, O; Palmer, J; Sowers, J | 1 |
| Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K | 1 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Davidson, MH | 1 |
| Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Iwashita, M; Kono, S; Sasaki, J | 1 |
| Gennimata, V; Ikonomidis, I; Kotsis, V; Lekakis, J; Pitiriga, V; Protogerou, A; Zakopoulos, N | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Hérnandez, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 1 |
| Nesto, RW; Singh, PP | 1 |
| Aretini, A; Gentile, MT; Landolfi, A; Lembo, G; Maffei, A; Marino, G; Passarelli, F; Poulet, R; Vasta, A; Vecchione, C | 1 |
| Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ | 1 |
| Shaley, FM | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| DiTusa, L; Luzier, AB | 1 |
| Chan, E; Charles, MA; Pan, J; Van, JT; Wasty, T; Wu, X | 1 |
| Berk-Planken, I; de Konig, I; Hoogerbrugge, N; Jansen, H; Stolk, R | 1 |
10 review(s) available for atorvastatin and Diabetes Mellitus
| Article | Year |
|---|---|
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Diabetes Mellitus; Female; Humans; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal | 2022 |
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.
Topics: Atorvastatin; Cohort Studies; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Quinolines; Retrospective Studies; Rosuvastatin Calcium | 2022 |
[Elucidation of a New Mechanism of Onset of Insulin Resistance: Effects of Statins and Tumor Necrosis Factor-α on Insulin Signal Transduction].
Topics: Adipocytes; AMP-Activated Protein Kinases; Animals; Atorvastatin; Diabetes Mellitus; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Mice; Mitogen-Activated Protein Kinase Phosphatases; Phosphorylation; rho-Associated Kinases; rhoA GTP-Binding Protein; Serine; Signal Transduction; Tumor Necrosis Factor-alpha; Tyrosine | 2018 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
Statins and CVD prevention in the diabetic population: implications of the CARDS trial.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Risk Factors | 2005 |
Statins: beneficial or adverse for glucose metabolism.
Topics: Atorvastatin; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2006 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
20 trial(s) available for atorvastatin and Diabetes Mellitus
| Article | Year |
|---|---|
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
Topics: Adult; Atorvastatin; Cataract; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome; Young Adult | 2023 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Bipolar Disorder; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus; Humans; Lithium; Middle Aged; Pilot Projects; Young Adult | 2021 |
Statins Are Associated With Increased Insulin Resistance and Secretion.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Gastric Stump; Humans; Lipoproteins; Male; Middle Aged; Prospective Studies; Triglycerides | 2018 |
Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
Topics: Atorvastatin; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Clinical Protocols; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Metabolic Syndrome; Prospective Studies; Quinolines; Republic of Korea; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
Topics: Aged; Atorvastatin; Clopidogrel; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Thrombosis; Ticlopidine | 2014 |
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Topics: Atorvastatin; Body Weight; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Style; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Weight Loss | 2014 |
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acut
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Topics: Adiponectin; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Female; Fluorobenzenes; Glucose; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sulfonamides; Triglycerides | 2011 |
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Time Factors; Treatment Outcome | 2012 |
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Topics: Adult; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Biological; Pyrroles | 2012 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior | 2005 |
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2007 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Atorvastatin, diabetic dyslipidemia, and cognitive functioning.
Topics: Aged; Atorvastatin; Cholesterol; Cognition; Diabetes Complications; Diabetes Mellitus; Fasting; Heptanoic Acids; Humans; Hyperlipidemias; Middle Aged; Pyrroles; Time Factors; Triglycerides | 2002 |
55 other study(ies) available for atorvastatin and Diabetes Mellitus
| Article | Year |
|---|---|
Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study.
Topics: Asian People; Atorvastatin; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors; Rosuvastatin Calcium | 2022 |
Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.
Topics: Aged; Atorvastatin; Cross-Sectional Studies; Diabetes Mellitus; Glucose; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Prediabetic State; Rosuvastatin Calcium; Simvastatin; Spain | 2022 |
Lycopene ameliorates hyperlipidemia via potentiation of AMP-activated protein kinase and inhibition of ATP-citrate lyase in diabetic hyperlipidemic rat model.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Atorvastatin; ATP Citrate (pro-S)-Lyase; Biomarkers; Coenzyme A; Diabetes Mellitus; Fatty Acid Synthases; Glutathione; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lycopene; Malondialdehyde; Multienzyme Complexes; Oxo-Acid-Lyases; Rats; Streptozocin; Tumor Necrosis Factor-alpha | 2022 |
Vitamin D3 intake as modulator for the early biomarkers of myocardial tissue injury in diabetic hyperlipidaemic rats.
Topics: Animals; Atorvastatin; Biomarkers; Cholecalciferol; Diabetes Mellitus; Rats; Rats, Wistar | 2022 |
[Dyslipidemia Secondary to Hypothyroidism and Cholestasis].
Topics: Atorvastatin; Autoimmune Diseases; Cholestasis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Liver Cirrhosis, Biliary; Middle Aged; Obesity; Thyroxine; Withholding Treatment | 2020 |
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins.
Topics: Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Registries; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Treatment Outcome | 2021 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus; Disease Progression; Electronic Health Records; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Prediabetic State; Quinolines; Republic of Korea; Retrospective Studies | 2017 |
The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Renal Insufficiency, Chronic; Simvastatin; Time Factors | 2017 |
Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins.
Topics: Adipose Tissue; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Echocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pericardium; Predictive Value of Tests; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Seoul; Time Factors; Treatment Outcome | 2018 |
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Middle East; Rosuvastatin Calcium; Sex Characteristics; Simvastatin | 2018 |
Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
Topics: Animals; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Receptor for Advanced Glycation End Products | 2018 |
Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Glucose; Diabetes Mellitus; Dyslipidemias; Female; Follow-Up Studies; Glucose Metabolism Disorders; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Simvastatin; Young Adult | 2017 |
Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus.
Topics: Administrative Claims, Healthcare; Aged; Atorvastatin; Biomarkers; Databases, Factual; Diabetes Mellitus; Drug Prescriptions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Medicare Part D; Myocardial Infarction; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Time Factors; Treatment Outcome; United States | 2018 |
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction.
Topics: Atorvastatin; Biomarkers; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Quinolines; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium | 2018 |
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Diabetes Mellitus; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2019 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Socioeconomic Factors | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes.
Topics: Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Monitoring; Dyslipidemias; Female; Humans; Incidence; Male; Middle Aged; Republic of Korea; Risk Factors | 2015 |
Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Portugal; Quality-Adjusted Life Years; Risk Factors; Rosuvastatin Calcium; Smoking | 2015 |
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking | 2015 |
Different effects of statins on induction of diabetes mellitus: an experimental study.
Topics: Atorvastatin; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Pravastatin; Quinolines; Rosuvastatin Calcium; Signal Transduction; Structure-Activity Relationship | 2015 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
Toxicity of Atorvastatin on Pancreas Mitochondria: A Justification for Increased Risk of Diabetes Mellitus.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Atorvastatin; Cytochromes c; Diabetes Mellitus; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Swelling; Oxidative Stress; Pancreas; Rats, Sprague-Dawley; Reactive Oxygen Species; Risk Assessment; Signal Transduction; Time Factors | 2017 |
Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3; Immunoblotting; Immunohistochemistry; Kidney; Male; Mice; NADPH Oxidase 4; NADPH Oxidases; Phosphorylation; Protective Agents; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Up-Regulation | 2016 |
A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Health Maintenance Organizations; Heptanoic Acids; Humans; Preferred Provider Organizations; Pyrroles; Simvastatin; Treatment Outcome; United States | 2008 |
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk; Simvastatin; United States | 2008 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Necrosis; Pilot Projects; Pioglitazone; Prospective Studies; Pyrroles; Registries; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Heart Failure; Heart Ventricles; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrroles; Retrospective Studies; Ventricular Premature Complexes | 2009 |
Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Topics: Aged; Angiopoietin-1; Angiopoietin-2; Antigens, CD; Antigens, CD34; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor A | 2010 |
Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Diabetes Mellitus; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2010 |
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Topics: Absenteeism; Adult; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Employment; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Simvastatin | 2011 |
Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes.
Topics: Adult; Aged; Angiogenic Proteins; Asian People; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Diabetes Mellitus; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Pyrroles; von Willebrand Factor; White People | 2011 |
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Pyrroles; Skin | 2003 |
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms | 2004 |
[Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Triglycerides | 2005 |
[Considerable LDL lowering is advantageous].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Placebos; Pyrroles; Risk; Risk Factors; Triglycerides | 2005 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link?
Topics: Adult; Aged; Arteries; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Constriction, Pathologic; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Smoking; Vascular Resistance | 2006 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
A novel mechanism of action for statins against diabetes-induced oxidative stress.
Topics: Animals; Antioxidants; Aorta; Atorvastatin; Diabetes Complications; Diabetes Mellitus; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Inbred C57BL; Oxidative Stress; Polyisoprenyl Phosphates; Pyrroles; rac GTP-Binding Proteins | 2007 |
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States | 2007 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pyrroles; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
Topics: Atorvastatin; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrroles; Retrospective Studies; Triglycerides | 2002 |